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Abstract: We aimed to analyze the incidence of Guillain-Barré syndrome (GBS) and its association with
influenza vaccination (IV) in the elderly population. This study included 2470 patients hospitalized
with GBS (G61.0) between 2014 and 2016 based on the Korean National Health Insurance Service
(NHIS) claims data. We reviewed every medical claim in the 42 days preceding GBS diagnosis
looking for precedent causes of GBS. To assess the relationship between IV and the development
of GBS, data from the NHIS and the National Vaccination Registry were combined and analyzed.
Using a self-controlled case series (SCCS) approach, we calculated the incidence rate ratio by setting
the risk period as 42 days following vaccination. The annual background incidence of GBS was
estimated at 4.15 per 100,000 persons. More than half of the patients with newly developed GBS had
a previous infection or surgery. The incidence of GBS within 42 days of IV was estimated at 0.32 per
100,000 vaccinated persons. SCCS analysis showed that the risk of GBS was not significantly higher.
While GBS can potentially develop from various infections, no association was found between GBS
and IV. These results will contribute to developing an evidence-based vaccine policy that includes a
clear causality assessment of adverse events.
Keywords: Guillain-Barré syndrome; influenza vaccine; incidence; self-controlled case series
1. Introduction
Influenza is a common infectious disease considered to be socially and economically burdensome,
especially because of its frequent complications [1,2]. Vaccination is the most effective method for
preventing influenza [3,4], and it is especially recommended for high-risk groups [5]. In Korea,
influenza vaccination has been included in the National Immunization Program (NIP) since 1997 [6],
and its coverage among the elderly population reached levels above 85% in 2018, which is the highest
coverage rate in the world [7]. In comparison, Japan reported a coverage rate of 48% in 2017, and China
reported a rate of 38.7% in Beijing in 2012 [8].
Importantly, concerns about adverse events following immunization (AEFI) are increasing.
One AEFI of particular interest, which may occur after influenza vaccination, is Guillain-Barré
syndrome (GBS) [9]. GBS is a rare but severe type of peripheral neuropathy [10]. The incidence of GBS
increases with age and is higher in men than in women. For example, one meta-analysis found that,
the incidence of GBS among people aged 60–69 and 70–79 years was 1.85 and 2.22 per 100,000 person
years, respectively; whereas, the incidence among people aged 20–29 years was 0.90 per 100,000 person
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years [11]. Although a variety of infections have been reported as causes of GBS [12,13], influenza
vaccination stands out as it has been repeatedly mentioned as possibly causative of GBS [14,15].
Despite the efforts of the WHO vaccine safety committee and the Institute of Medicine, the potential
mechanism of action by which influenza vaccination could cause GBS is unknown [16,17]. Nevertheless,
a recent meta-analysis found a significant association between influenza vaccination and the incidence
of GBS [18]. However, the results varied depending on the study year, study design, data source,
and region. Furthermore, Kwong et al. (2013) reported that GBS was more associated with influenza
itself than with influenza vaccination [19], insisting instead that influenza vaccination could decrease
GBS incidence.
Notably, most of the studies to date have been conducted in Western countries, while evidence
concerning the association and basic epidemiologic information about GBS in Asian populations is
lacking. Moreover, there has been recent advancements as well as diversification in epidemiological
methodology. In particular, the self-controlled case series (SCCS) method is now widely recognized as a
valid approach to assess the association between vaccination and AEFI, while minimizing confounders
associated with vaccinated individuals, through the use of cases themselves as controls [20–22].
Therefore, we conducted a nationwide study to examine the epidemiologic characteristics of GBS
in the Korean elderly population. Since the development of GBS increases with age and the Korean
NIP offers free vaccination against influenza for the elderly, our study focused on the population
aged 65 years or older. Specifically, we aimed to: (1) estimate the incidence rate of GBS regardless
of vaccination; (2) estimate the incidence rate of GBS among vaccinated people; and (3) examine
pre-existing conditions that could lead to GBS. In addition, we aimed to (4) assess the association
between influenza vaccination and GBS development following vaccination by merging the National
Vaccination Registry data and the National Health Insurance Service (NHIS) claims data. These results
will contribute to the development of an evidence-based vaccine policy, and help the National Vaccine
Injury Compensation program, which is in urgent need of a clear causality assessment for AEFI.
2. Materials and Methods
2.1. Data Sources
To examine the epidemiologic characteristics of GBS, we first estimated its incidence rate regardless
of vaccination. We used the claims data from the NHIS to examine any pre-existing conditions that
may lead to the development of GBS. The NHIS claims data covers the entire population of Korea
and provides selected demographic information (i.e., sex, age, residence area, economic status,
and disability) of the enrollees, as well as records of medical interventions including diagnoses,
procedures, and prescribed drugs [23].
To estimate the incidence rate of GBS among vaccinated individuals and to assess the association
between influenza vaccination and GBS, we used two national datasets: the vaccination registry
established by the Korea Centers for Diseases Control and Prevention (KCDC) [24] and the NHIS
claims data. The KCDC keeps a vaccination registry for all vaccines covered by the NIP, in which
physicians have to register the vaccination information when they inoculate patients within the NIP.
The vaccination registry data includes demographic characteristics of the vaccinated subjects (i.e., sex,
age, and residence area), and information about the vaccine (i.e., date of vaccination, type of vaccine,
and dose). We merged the vaccination registry data from 2014 to 2016 with the NHIS claims data
from 2013 to 2017 using de-identified individual identification numbers. We covered two seasons of
influenza vaccination: the 2014–2015 season, corresponding to the period from July 2014 to June 2015,
and the 2015–2016 season, corresponding to the period from July 2015 to June 2016.
This study protocol was approved by the Institutional Review Board of Yonsei University
Gangnam Severance Hospital, Seoul, Republic of Korea (IRB No. 3-2018-0116). The requirement to
obtain informed consent was waived due to the untraceable and de-identified nature of the secondary
claims data. This study was performed in accordance with the ethical guidelines of the Declaration of
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Helsinki of the World Medical Association. The Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) statement was used for reporting [25].
2.2. Guillain-Barré Syndrome Case Ascertainment
A new GBS onset was defined as a case of hospitalization with a primary diagnosis of GBS
(international classification of disease (ICD)-10th code G61.0) and identified as follows. For each
one-year study period (July 2014–June 2015 or July 2015–June 2016), we identified the patients having
hospitalization records with a primary diagnosis of GBS, aged 65 years or older at the time of
hospitalization. To define a new occurrence of GBS, we set the year before the earliest hospitalization
with GBS in the study period as a washout period. We excluded patients if they had records of
outpatient visits or hospitalization with a diagnosis of GBS or polyneuropathy (ICD-10th codes
G61.8, G61.9, G62.8, or G62.9) during the washout period [19]. Patients who had outpatient visits
due to GBS, or outpatient visits or hospital admission due to polyneuropathy during the month
before the hospitalization with GBS, were considered to have received pre-treatments associated
with hospitalization due to GBS, and therefore included as incident GBS cases. Figure 1 shows how
the incident GBS cases were identified from the NHIS claims data.
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Figure 1. Flow chart of the study population selection. (a Excluding patients with a history of GBS
or inflammatory demyelinating polyneuropathy during the past 1 year from the time of the first GBS
admission in the study period; Season 1: July 2014–June 2015; Season 2: July 2015–June 2016).
2.3. Data Analysis
We first estimated the background incidence of GBS, which occurs regardless of influenza
vaccination. Next, the incidence of GBS that occurred within 42 and 90 days after influenza vaccination
was calculated. Then, we analyzed the frequency of potential causes of GBS in the medical history
within 42 days of the occurrence date of GBS. Finally, sing the SCCS method, the relative incidence of
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GBS in the exposed period compared to the unexposed period of the influenza vaccine was calculated
for those with GBS who had received influenza vaccination.
2.3.1. Incidence Rate of GBS
The incidence rate of GBS was estimated based on two measurements for each influenza season:
one was the background incidence rate of GBS regardless of vaccination and the other one was
the incidence rate of GBS following influenza vaccination within the risk period of 42 days (6 weeks)
or 90 days (3 months). The background incidence rate of GBS per 100,000 elderly person years was
calculated by dividing the number of new patients with GBS per year by the size of the elderly
population for the corresponding year, obtained from Statistics of Korea [26]. In order to estimate
the incidence rate of GBS following influenza vaccination, we selected patients who had a history
of influenza vaccination among the new patients with GBS, from which we extracted those who
developed GBS within 42 days (6 weeks) or 90 days (3 months) after the influenza vaccination [19,27].
Thus, the incidence rate of GBS following the influenza vaccination per 100,000 elderly persons was
calculated by dividing the number of these patients by the total number of elderly people vaccinated
against influenza.
Background incidence rate of GBS among the elderly per year = (Number of elderly patients with
new GBS/total size of elderly population) × 100,000.
Incidence rate of GBS within 42 days following influenza vaccination among the elderly = (Number
of elderly patients vaccinated against influenza and experiencing GBS within 42 days following
vaccination/total number of elderly people vaccinated against influenza) × 100,000.
Incidence rate of GBS within 90 days following influenza vaccination among the elderly = (number
of elderly patients vaccinated against influenza and experiencing GBS within 90 days following
vaccination/total number of elderly people vaccinated against influenza) × 100,000.
Demographic and health care utilization characteristics of the incident GBS patients were examined,
including gender, age, type of national health security program, month of hospital admission, specialty
department in which they were treated when hospitalized, type of healthcare institution utilized,
and registration in the rare-disease registry.
2.3.2. Precedent Medical Events
Up to 70% of GBS cases are known to be caused by precedent infections including influenza
virus infection [28,29]. Additionally, studies have shown that surgery and influenza vaccination can
cause GBS [30]. The leading causes of GBS are believed to be cytomegalovirus and upper respiratory
tract or gastrointestinal tract infections [12,13]. We analyzed the frequency distribution of precedent
infections, surgeries, or influenza vaccination, observed within 42 days of the date of admission with
new-onset GBS. The precedent infections examined were selected based on previous literature as well
as consultation with a panel of ten clinical experts in Korea [12,13,30–32]. Supplemental Table S1 shows
the ICD-10th diagnostic codes for the infections included in our analysis.
2.3.3. Association between Influenza Vaccination and GBS
To assess the association between the influenza vaccination and the development of GBS,
we employed the SCCS study design. The SCCS approach sets the risk period and compares
the number of events of interest between the risk period and the control (non-risk or baseline) period
within the same study subject [20]. The risk period is defined as the time during which immunization
has a high probability of causing AEFI. It is generally set based on biological plausibility and half-life
exposure, but also by empirical or customary consensus. It is also possible to define one or more risk
periods [20–22].
Based on previous literature and consultation with clinical experts, we set the risk period for
our analysis at 42 days after influenza immunization, meaning that the influenza vaccination could
cause GBS within the 42 days following vaccination [33,34]. The risk period was further divided into
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the sub-periods ≤3, 4–7, 8–14, and 15–42 days to analyze the causal relationship between vaccination
and GBS according to different risk periods (Figure 2). Additionally, the period of 43–90 days was set
as an additional risk period to examine the possibility of GBS development even after a considerable
time gap following influenza vaccination. The control period was defined as having no relationship
with influenza vaccination, namely the period before or more than 90 days after vaccination.
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Figure 2. The concept of the self-controlled case series approach in the 2014–2015 season.
Using conditional Poisson regression analysis, we estimated the incidence rate ratio (IRR)
comparing the incidence of GBS in the risk period with that in the control period. All data analyses
were performed using the SAS program (9.4 version, Cary, NC, USA). The SAS code used to
perform SCCS was adapted from the instructions and macrocode provided by The Open University
(http://statistics.open.ac.uk/sccs).
2.4. Data Availability Statement
Data are available upon request due to data protection guidelines laid down by the Korean data
privacy regul tion. Data access r quests may be made t the Institutional Review Board of Yonsei
University Gangnam Severance Hospital at gsirb@yuhs.ac.
3. Results
3.1. The Background Incidence Rate and Characteristics of GBS Patients
Out of 1191 patients hospitalize with GBS from July 2014 to June 2015, we identified 262 patients
aged 65 years or older with new-onset GBS (Figure 1). In addition, out of 1279 patients hospitalized
with GBS from July 2015 to June 2016, 271 patients aged 65 years or older with new-onset GBS were
identified. The annual incidence rate of GBS among the population aged 65 years or older was
calculated to be 4.16 per 100,000 persons in the 2014–2015 season and 4.14 per 100,000 persons in
the 2015–2016 season. The incidence rate was higher among men than women (Table 1).








No. of Patients Incidence per 100,000 No. of Patients Incidence per 100,000 No. of Patients Incidence per 100,000
To al 533 4.15 262 4.16 271 4.14
Sex - - - - - -
Male 278 5.18 140 5.34 138 5.02
Female 255 3.41 122 3.32 133 3.50
Age (years) - - - - - -
65–74 315 4.01 158 4.07 157 3.94
75–84 192 4.43 95 4.50 97 4.36
≥85 26 2.37 9 1.70 17 2.99
Vaccines 2020, 8, 431 6 of 12
More than half of the elderly patients with new-onset GBS were aged 65–74 years (59.1%) and no
seasonality was observed in the development of GBS (Table 2). More than three quarters of the patients
with new-onset GBS were diagnosed in the department of neurology, and the majority of patients were
hospitalized in general or tertiary-care hospitals.












n % n % n %
Sex - - - - - -
Male 278 52.16 140 53.44 138 50.92
Female 255 47.84 122 46.56 133 49.08
Age (years) - - - - - -
65–74 315 59.10 158 60.31 157 57.93
75–84 192 36.02 95 36.26 97 35.79
≥85 26 4.88 9 3.44 17 6.27
Type of national health security
program - - - - - -
National Health Insurance 497 93.25 248 94.66 249 91.88
Medical Aid 36 6.75 14 5.34 22 8.12
Month of hospital admission - - - - -
July 56 10.51 25 9.54 31 11.44
August 49 9.19 27 10.31 22 8.12
September 40 7.50 18 6.87 22 8.12
October 28 5.25 12 4.58 16 5.90
November 30 5.63 10 3.82 20 7.38
December 35 6.57 22 8.40 13 4.80
January 43 8.07 25 9.54 18 6.64
February 37 6.94 16 6.11 21 7.75
March 58 10.88 29 11.07 29 10.70
April 50 9.38 21 8.02 29 10.70
May 62 11.63 35 13.36 27 9.96
June 45 8.44 22 8.40 23 8.49
Physician specialty treating GBS - - - - - -
Neurology 413 77.49 202 77.10 211 77.86
Rehabilitation 35 6.57 20 7.63 15 5.54
Internal medicine 36 6.75 16 6.11 20 7.38
Neurosurgery 25 4.69 10 3.82 15 5.54
Others 24 4.50 14 5.34 10 3.69
Type of healthcare institutions
treating GBS - - - - - -
Tertiary-care hospital 302 56.66 151 57.63 151 55.72
General hospital 111 20.83 100 38.17 11 4.06
Hospital 13 2.44 7 2.67 6 2.21
Long-term care hospital 7 1.31 4 1.53 3 1.11
Rare disease registry - - - - - -
Yes 435 81.61 208 79.39 227 83.76
No 98 18.39 54 20.61 44 16.24
(GBS: Guillain-Barré syndrome).
3.2. Prevalence of Precedent Medical Events before the Development of Guillain-Barré Syndrome
As shown in Table 3, more than half of the patients with new-onset GBS had precedent medical
events such as infections, surgery, or influenza vaccination within 6 weeks prior to onset, which may
be potential causes for the development of GBS. Upper respiratory infections showed the highest
prevalence in GBS patients (more than 40%), followed by gastrointestinal (GI) infection (more than
10%). Among pathogens, influenza virus was the most frequently reported (9.57%), followed by herpes
zoster virus (2.25%), and herpes simplex virus (0.95%). However, only one case of Campylobacter
jejuni, which is known to cause GBS [12,13], was reported, and no patient had been infected with
the cytomegalovirus or the Epstein–Barr virus. Approximately 5–7% of the GBS patients had received
the influenza vaccine within 6 weeks of hospitalization with GBS.
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n % n % n %
Any infection/surgery/influenza vaccine 312 58.54 154 58.78 158 58.30
Anatomical infection site
Upper respiratory 225 42.21 110 41.98 115 42.44
Lower respiratory 1 0.19 0 0.00 1 0.37
Gastro-intestinal 65 12.20 31 11.83 34 12.55
Pathogen
Malaria 0 0.00 0 0.00 0 0.00
Tsutsugamushi 3 0.56 0 0.00 3 1.11
Campylobacter 1 0.19 1 0.38 0 0.00
Cytomegalovirus 0 0.00 0 0.00 0 0.00
Epstein-Barr virus 0 0.00 0 0.00 0 0.00
Herpes simplex virus 5 0.94 3 1.15 2 0.74
Varicella (Chickenpox) 0 0.00 0 0.00 0 0.00
Herpes zoster virus 12 2.25 4 1.53 8 2.95
Mycoplasma 0 0.00 0 0.00 0 0.00
Hemophilus influenzae 0 0.00 0 0.00 0 0.00
Influenza virus 51 9.57 26 9.92 25 9.23
Parainfluenza virus 0 0.00 0 0.00 0 0.00
Other viruses 0 0.00 0 0.00 0 0.00
Other infections 0 0.00 0 0.00 0 0.00
Surgery 44 8.26 23 8.78 21 7.72
Influenza vaccine (trivalent) * 32 5.82 13 4.96 19 7.01
* All influenza vaccines to be studied are trivalent vaccines, and the compositions of the vaccines are as follows:
In the 2014–2015 season: An A/California/7/2009 (H1N1)pdm09-like virus; an A/Texas/50/2012 (H3N2)-like virus;
and a B/Massachusetts/2/2012-like virus. In the 2015–2016 season: An A/California/7/2009 (H1N1)pdm09-like virus;
an A/Switzerland/9715293/2013 (H3N2)-like virus; and a B/Phuket/3073/2013-like virus [5].
3.3. Incidence Rate of GBS among the Elderly Vaccinated against Influenza
Among the incident GBS patients, 320 had a record of influenza vaccination (145 in the 2014–2015
season and 175 in the 2015–2016 season). Among them, 32 experienced the onset of GBS within 42 days
following the influenza vaccination, and 74 within 90 days. During the two influenza seasons, the GBS
incidence rate within 42 days and 90 days of influenza vaccination among the population aged 65 years
or older was 0.32 and 0.73 per 100,000 persons vaccinated against influenza, respectively (Table 4).








No. of Patients Incidence per 100,000Vaccinated No. of Patients
Incidence per 100,000
Vaccinated No. of Patients
Incidence per 100,000
Vaccinated
Within 42 days post vaccination
Total 32 0.32 13 0.28 19 0.35
Male 16 0.38 6 0.31 10 0.45
Female 16 0.27 7 0.25 9 0.28
Within 90 days post vaccination
Total 74 0.73 39 0.83 35 0.65
Male 33 0.79 20 1.03 13 0.58
Female 41 0.69 19 0.69 22 0.69
3.4. Association between Influenza Vaccination and GBS Development
Using the SCCS approach, we estimated the IRR of GBS for each risk period to assess the association
between influenza vaccination and the development of GBS. The IRR for the risk periods of 4–7 days,
8–14 days, 15–42 days, and 43–90 days were 0.83 (95% confidence interval [CI]: 0.26–2.58), 0.94 (95%
CI: 0.42–2.12), 0.86 (95% CI: 0.56–1.34), and 0.89 (95% CI: 0.64–1.25), respectively (Table 5). None of
the IRRs were statistically significant, suggesting the lack of association between influenza vaccination
and the development of GBS. Subgroup analysis by sex and age consistently showed non-significant
IRRs (Supplemental Table S2).
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Table 5. Results of conditional Poisson regression analysis to assess the association between influenza























(78.44) 1.00 - -
110
(75.86) 1.00 - -
141
(80.57) 1.00 - -
0–3 0 (0) - - - 0 (0) - - - 0 (0) - - -
4–7 3(0.94) 0.83 0.26 2.58 1 (0.69) 0.63 0.09 4.48 2 (1.14) 0.98 0.24 3.97
8–14 6(1.88) 0.94 0.42 2.12 1 (0.69) 0.36 0.05 2.56 5 (2.86) 1.40 0.58 3.42
15–42 21(6.56) 0.86 0.56 1.34 9 (6.21) 0.80 0.41 1.59
12
(6.86) 0.91 0.52 1.61
43–90 39(12.19) 0.89 0.64 1.25
24
(16.55) 1.25 0.80 1.94
15
(8.57) 0.61 0.36 1.05
(CI, confidence interval; IRR, incidence rate ratio).
4. Discussion
This epidemiological study examined the incidence rate of GBS and assessed the association
between influenza vaccination and the development of GBS in the elderly population. We estimated
the background annual incidence rate of GBS at 4.14–4.16 per 100,000 elderly persons. The incidence
was higher in men than in women, with an incidence ratio of 1.5 without seasonality. In addition,
the incidence rates of GBS within 42 and 90 days following influenza vaccination were estimated as
0.32 and 0.72 per 100,000 elderly persons vaccinated, respectively. In this study, precedent infection
or a history of surgery within 42 days before the incidence of GBS were found in more than half of
the patients. The most common infections were upper respiratory infection and GI infection, which are
very common in the general population. Using the SCCS approach, we found that the IRRs of GBS for
each risk period were not statistically significant.
The incidence rate of GBS (4.14–4.16 per 100,000 elderly persons) in this study is higher than
that previously reported in a meta-analysis of an elderly population in their 70s (2.22 per 100,000
elderly persons) [11]. Importantly, in Korea, to input the diagnostic code of GBS for a reimbursement,
invasive tests such as lumbar puncture and electrodiagnostic tests are required. Because of this,
it is likely that GBS is more easily detected in Korea, which has relatively good health accessibility
given the universal health insurance system operated by the government [35]. The incidence ratio
of males to females in this study (1.5) is similar to the ratio of 1.8 reported in previous studies [36].
Male predominance in the incidence of GBS is a well-known phenomenon, but the cause is still
unclear [11]. In this study, the incidence rates of GBS after influenza vaccination within 42 days were
higher than that reported by the WHO GACVS in all age groups (0.1–0.2 per 100,000 persons who
received influenza vaccination) [16], but lower than the GBS incidence in the elderly aged 65 years
and older regardless of influenza vaccination in the present study (4.1–4.2 per 100,000 person years).
In this study, more than half of the patients with a new GBS had precedent infection or a
history of surgery within 42 days prior to the incidence of GBS. This suggests that a very cautious
approach is required to determine the causes of GBS. It is noteworthy that approximately 5–7% of
the patients with GBS were vaccinated against influenza, while approximately 10% were infected with
the influenza virus itself within 42 days before hospitalization with GBS. Although this study does not
yield an incidence rate for each precedent cause of GBS, it suggests that additional consideration is
needed given the magnitude of the risk that the influenza vaccine and influenza virus itself confer to
the incidence of GBS. For example, Kwong et al. (2013) reported that influenza infection (relative risk
15.81; 95% CIs 10.28–24.32) increased the risk of GBS more than the influenza vaccine (relative risk 1.52;
95% CIs 1.17–1.99) [19]. Therefore, in order to balance the benefits and risks of influenza vaccination,
it is important to establish policies for influenza vaccination while considering the management of
GBS incidence.
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To assess the casual association between the incidence of GBS and influenza vaccination,
we integrated the national vaccination registry and NHIS claims data for the entire elderly population.
Using the SCCS method, we found no significant causal association. However, this association remains
controversial. As a result of combining 22 research findings from the latest studies by Arias et al. (2015),
the relative risk of GBS occurrence after seasonal influenza vaccination was 1.22 (95% CI: 1.01–1.48) [18].
However, among the 22 studies, the relative risk of the four that used the SCCS method like the present
study was 1.14 (95% CI, 0.78–1.66), which was not statistically significant and thereby suggests a
lack of a significant association of GBS with influenza vaccination, in agreement with the results of
the present study [18]. The SCCS method has an advantage in controlling confounding variables that
are not measured or not time-dependent in cases where it is difficult to define a non-exposed group,
such as people not vaccinated with influenza, due to its high coverage rate. The cases contain their
own controls, allowing us to compare the number of events that occurred in the risk-period with those
occurring in the control period. The IRR calculated from the SCCS analysis represents the relative
incidence of the risk periods with respect to the control period. Therefore, this value does not rely on
the comparison of incidence in people who have and have not been vaccinated.
The following points must be noted in interpreting the results of this study. First, we used
hospitalization status and disease codes/order in the health insurance claims data instead of checking
the medical charts of treatment in defining GBS patients. Therefore, the number of patients may
have been underestimated or overestimated, depending on the accuracy of diagnosis. However,
the code diagnosing of GBS is G61.0, which is a very specific code, and according to the experts’ panel
the approach of selecting inpatients diagnosed with GBS as the primary diagnosis of the study subjects
was deemed adequate. Moreover, previous studies conducted in other countries also selected inpatients
with G61.0 as the definition of GBS cases [19]. For example, a study in Korea that defined GBS by
reviewing medical records also reported that the G61.0 code was recorded in the primary diagnosis or
secondary diagnosis [37]. This implies that defining the inpatients with G61.0 as the primary diagnosis
of GBS cases is a valid approach, since the G61.0 code is expected to have a high positive predictive
value (PPV). In an algorithmic approach to the diagnosis of GBS based on claims data, an algorithm
including a primary inpatient GBS code and a neurologist visit associated with the GBS code gave
the highest PPV of 0.70 [38]. Second, it is difficult to specify the GBS onset date, because of the nature of
the disease. Thus, the onset date is considered to coincide with the date of admission when interpreting
the IRR. To overcome this limitation, we defined an extra risk period (43–90 days) and sub-divided
the risk period into the sub-periods ≤3, 4–7, 8–14, and 15–42 days. Third, the absolute incidence of GBS
following influenza vaccination cannot be calculated in the SCCS method. This research design selects
patients with GBS and patients with records of influenza vaccination as the study subjects, and thus can
efficiently estimate the IRR, but does not estimate the incidence of GBS among all influenza-vaccinated
patients. However, efforts were made to overcome the limitations of the SCCS method by also
estimating the GBS incidence rate within the risk period following influenza vaccination.
The analysis of the total number of GBS cases diagnosed in the Korean elderly population
showed that the background incidence of GBS is slightly higher than in other countries. However,
as shown in our results, more than half of the GBS patients had a history of common infections
or surgery and influenza vaccination was considered one of such possible causes. Thus, to make
the evidence-based vaccine policy that minimizes GBS as AEFI, the correct diagnosing of GBS as well as
a thorough review of a patient’s medical history are critical. Additionally, the statistically insignificant
IRR results of the GBS incidence after influenza vaccination compared to unexposed risk period are
meaningful for the elderly population. This result can be specifically applied to the process of decision
making in the Korean National Vaccine Injury Compensation Program.
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In order to accurately diagnose GBS and implement a comprehensive vaccine policy,
the government should sustainably perform a long-term pharmacoepidemiologic study and establish
an active monitoring system that enables the tracking of vaccination history and AEFI incidence in a
unified database. In addition, clinicians should be knowledgeable about patients’ health conditions
such as a history of infections or surgery as well as vaccinating when diagnosing GBS.
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